Use of services and costs in patients with influenza (H1N1) 2009 in Spain: Background and research protocol;Utilización de servicios y costes de los pacientes con gripe (H1N1) 2009 en España: Antecedentes y protocolo de investigación

Revista Espanola de Salud Publica

Volumn 85, Issue 1, 2011, Pages 19-31

  Garin, Olatz ^a,b   Galante, Mariana ^a   García Altés, Anna ^c   Sicuri, Elisa ^a,d   Cots, Francesc ^e   Nebot, Manel ^f   Ferrer, Montse ^a,b,g   Dominguez, Angela ^h   Alonso, Jordi ^a,b,i  

^a CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c Agència d'Informació Avaluació i Qualitat en Salut Generalitat ^*  (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e Servicio de Evaluación de Epidemiología Clínica   (Spain)

^f Servicio de Evaluación y Métodos de Investigación   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Health economics; Health services research; Human; Influenza

Indexed keywords

ARTICLE; COST; ECONOMICS; HEALTH SERVICE; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; METHODOLOGY; RESEARCH; SPAIN; UTILIZATION REVIEW;

COSTS AND COST ANALYSIS; HEALTH SERVICES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; RESEARCH; SPAIN;

EID: 79960229464     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun Dis Public Health. 2000; 3(1):32-38.
2. ThompsonWW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292(11):1333-1340. (Pubitemid 39223224)
3. McBean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med. 1993; 153(18):2105-2111. (Pubitemid 23286463)
4. Webb SA, Pettila V, Seppelt I, Bellomo R, Bailey M, Cooper DJ et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009; 361(20):1925-1934.
5. Outbreak of swine-origin influenzaA(H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(17):467-470.
6. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med. 2003; 139(5 Pt 1):321-329.
7. Aballea S, de Juanes JR, Barbieri M, Martin M, Chancellor J, Oyaguez I et al. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.Vaccine. 2007; 25(39- 40):6900-6910. (Pubitemid 47391104)
8. Martin FJ. [Analysis of a economic model of a populational influenza immunization strategy in healthy employees]. Rev Esp Salud Publica. 2006; 80(3):219-231.
9. de Juanes JR, Cisterna R, Sanz J, Magaz S, Badia X. [Efficiency of influenza vaccination in the working population in Spain]. Gac Sanit. 2006; 20(2):101-107. (Pubitemid 43833890)
10. Brouwers L, Cakici B, Camitz M, Tegnell A, Boman M. Economic consequences to society of pandemic H1N1 influenza 2009 - preliminary results for Sweden. Euro Surveill 2009; 14(37).
11. Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A et al. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.Vaccine. 2010.
12. Smith RD, Keogh-Brown MR, Barnett T, Tait J. The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. BMJ. 2009; 339:b4571.
13. Keogh-Brown MR, Smith RD, Edmunds JW, Beutels P. The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands. Eur J Health Econ. 2009.
14. Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenzaAand B in high-risk patients. Pharmacoeconomics. 2001; 19(3):293-301. (Pubitemid 32230943)
15. Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess. 2002; 6(9):1-87.
16. Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics. 2000; 17(6):611-620. (Pubitemid 30407885)
17. Vindt Holm M, Gyldmark M, Holme Hansen E. Pharmacoeconomic assessment of oseltamivir in treating influenza-the case of otherwise healthy Danish adolescents and adults. Pharm World Sci. 2004; 26(6):339-345.
18. Ruf BR, Szucs T. Reducing the burden of influenza- associated complications with antiviral therapy. Infection. 2009; 37(3):186-196.
19. Oliva J, Del Llano J, Sacristan JA. [Analysis of economic evaluations of health technologies performed in Spain between 1990 and 2000.]. Gac Sanit. 2002; 16 Suppl 2:2-11.
20. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009; 339:b5106.
21. Dominguez SR, Daum RS. Physician knowledge and perspectives regarding influenza and influenza vaccination. Hum Vaccin. 2005; 1(2):74-79.
22. Vila-Corcoles A, Ochoa-Gondar O, Ester F, Sarra N, Ansa X, Saun N. Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up. BMC Public Health. 2006; 6:231.
23. Nichol KL. First do no harm: ensuring that healthcare workers vaccinate and are vaccinated. Infect Control Hosp Epidemiol. 2003; 24(11):799- 800. (Pubitemid 37516807)
24. Mykietiuk A, Carratala J, Dominguez A, Manzur A, Fernandez-Sabe N, Dorca J et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006; 25(7):457-462. (Pubitemid 44078598)
25. Fisman DN, Abrutyn E, Spaude KA, KimA, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis. 2006; 42(8):1093-1101.
26. Rubin JL, McGarry LJ, Klugman KP, Strutton DR, Gilmore KE, Weinstein MC. Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. BMC Infect Dis. 2010; 10(1):14.
27. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007; 25(27):5086-5096. (Pubitemid 46879994)
28. Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari NA et al. High costs of influenza: Direct medical costs of influenza disease in young children. Vaccine. 2010; 28(31):4913-4919.
29. Hassan F, Lewis TC, Davis MM, Gebremariam A, Dombkowski K. Hospital utilization and costs among children with influenza, 2003. Am J Prev Med. 2009; 36(4):292-296.
30. Simmerman JM, Lertiendumrong J, Dowell SF, Uyeki T, Olsen SJ, Chittaganpitch M et al. The cost of influenza in Thailand.Vaccine. 2006; 24(20):4417-4426. (Pubitemid 44308226)
31. Badia L, X, Roset GM, Frances Tudel JM, Alvarez SC, Rubio TC. [Study of flu costs]. Aten Primaria. 2006; 38(5):260-267.
32. Cox F, Khan ZM, Schweinle JE, Okamoto L, McLaughlin T. Cost associated with the treatment of influenza in a managed care setting. Med Gen Med. 2000; 2(4):E34.
33. Keren R, Zaoutis TE, Saddlemire S, Luan XQ, Coffin SE. Direct medical cost of influenza-related hospitalizations in children. Pediatrics. 2006; 118(5):e1321- e1327. (Pubitemid 46393636)
34. Ampofo K, Gesteland PH, Bender J, Mills M, Daly J, Samore M et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics. 2006; 118(6):2409- 2417. (Pubitemid 46397581)
35. Akazawa M, Sindelar JL, Paltiel AD. Economic costs of influenza-related work absenteeism. Value Health. 2003; 6(2):107-115. (Pubitemid 36403128)
36. Lambert SB, Allen KM, Carter RC, Nolan TM. The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children. Respir Res. 2008; 9:11.
37. Keren R, Zaoutis TE, Saddlemire S, Luan XQ, Coffin SE. Direct medical cost of influenza-related hospitalizations in children. Pediatrics. 2006; 118(5):e1321- e1327. (Pubitemid 46393636)
38. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990; 16(3):199-208.
39. Allsup SJ, Gosney MA. Anxiety and depression in an older research population and their impact on clinical outcomes in a randomised controlled trial. Postgrad Med J. 2002; 78(925):674-677. (Pubitemid 36084169)
40. Pradas VR, Villar FA, Puy Martinez-Zarate M. [Use of European Quality of Life-5 Dimensions (EQ-5D) questionnary to value the health related quality of life variation because of influenza]. Gac Sanit. 2009; 23(2):104-108.
41. Vademecum.es. CMP Medicom Editorial, S.A. Disponible en: http://www.vademecum.es [Citado el 21-02- 2010]. 2010.
42. Pachón J, Falguer M, Gudiol F, Sabria M, Alvarez Lerma F, Cordero E. Infecciones de las vías respiratorias Inferiores. Available at http://www.seimc.org/documentos/protocolos/clinicos/[Citado el 1-03-2010]. 2010.
43. Serrano Herranz R. Infecciones de las vías respiratorias Inferiores. Disponible en: http://www.fesemi.org/[Citado el 1-03-2010]. 77-96. 2010.
44. Cots F, Chiarello P, García Alzórriz E, Peláes E., Castells X., Raventós J. Cost de ĺactivitat asistencial. Variable de resultat per la gestió clínica. Fulls economics. 2010; 39: 14-25.
45. Encuesta anual de coste laboral 2008. Instituto Nacional de Estadística. Available http://www.ine.es/jaxi/menu.do?type= pcaxis&path=/t22/p132&file=inebase&N=&L=0 [Citado el 10-02- 2010].